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Background: 
Sickle cell disease is a very common 
hemoglobinopathy. The main goal of transfusion 
therapy in sickle cell disease is to prevent thrombotic 
events, improve tissue oxygenation and treat anaemia 
complications. However the risk of alloimunization is 
well known. Since 2001 our service has been doing a 
tight surveillance work in sickle cell patients, creating 
a database of about 15.000 studied blood donors. 
 Aims: 
We want to share our experience in transfusion of 
sickle cell patients and highlight the importance to 
have a computer database with compatible donors 
in order to reduce alloimunization in these patients.  
Methods: 
We have studied the above described donors for the following blood group systems ABO, Rh, Kell, Duffy, Kidd, MNSs, 
Lutheran, P (P1) and haemoglobin S. For each transfusion demand for these patients we research in our computer data 
base the more likely compatible donor.   
From January 2007 to January 2011 we studied 64 patients. To transfuse these patients we followed the protocol 
described above. We transfused these patients with red cells of compatible donors pre investigated. We perform pre 
transfusion tests in all patients. 
Results: 
Have been studied 64 patients who needed 
red cells transfusion, 30 were females and 
34 were males. The range of ages was from 
1 to 46 years old. 55 patients were black 
(85.9%). We have been able to transfuse 
these patients with red cells of 135 
compatible donors from database. We 
performed 439 red cell concentrate (RCC) 
transfusions (average per patient 6.85).The 
patient with the biggest supply was 
transfused with 22 RCC and we didn’t find 
in this case any clinically significant red cell 
alloantibody. We had 7 positive antibody 
screenings, 2 were anti-Lea, 2 anti-E and 3 
were inconclusive  
Summary/Conclusions:  
In our study all patients with clinically significant alloantibodies were previously transfused in other institution. We didn’t find 
any alloantibody in patients exclusively transfused in our department. Our experience transfusing sickle cell disease patients 
reveals that RCC compatible to antigens of the groups mentioned above greatly reduce alloimunization. Hence the importance 
of the existence in urgency blood department of an extended phenotype donors file. 
ISBT – Lisboa - 2011 
 64 Doentes estudados com idades entre 1 – 46A 
 55 Raça negra (85,9%) 
 135 Dadores compatíveis 
 439 CEs transfundidos 
 Doente com mais CEs transfundidos (22 Unidades) sem 
detecção de anticorpos significativos 
 Pesquisa de Anticorpos Irregulares positiva em 7 doentes 
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